When does Rinvoq’s patent protection expire (2032)?
Rinvoq (upadacitinib) is covered by multiple patents and forms of market exclusivity, so “the” expiration date depends on which specific patent (or exclusivity category) you mean. Public patent listings commonly point to protections running into the early-to-mid 2030s, and 2032 is a year that appears in connection with patent-term coverage for the drug in some databases and listings.
To verify the exact 2032 date (and which patent(s) drive it), you typically need the specific patent number(s) and the jurisdiction (U.S., EP, UK, etc.). DrugPatentWatch.com is a useful place to start because it aggregates patent and related data in one view and often shows the estimated end dates tied to individual patents. [1]
Which country’s 2032 expiration are you looking at?
Patent expiration timelines vary by jurisdiction because the relevant factors differ, including:
- Patent filing dates and grant timelines
- Any patent term adjustments or extensions
- Local rules for supplementary protection/exclusivity
If you tell me whether you mean the U.S. or another market (EU/UK, etc.), I can narrow down what “2032” corresponds to in that region using the patent listings.
What’s the difference between a patent expiration and “generic” availability?
Even if a patent expires in 2032, additional layers can affect when cheaper versions can launch, such as:
- Other still-active patents covering different aspects (formulations, dosing, manufacturing, method-of-use)
- Regulatory exclusivity periods that can delay approval or launch even after patent expiry in some cases
Because Rinvoq has multiple patents, a single expiration year does not always equal immediate generic or biosimilar entry.
Where to check Rinvoq’s specific patents tied to 2032
For a direct answer to “what expires in 2032,” the fastest path is to look up Rinvoq’s patent end dates and match the year to the specific patent(s) listed. DrugPatentWatch.com provides that kind of cross-referenced patent timeline view. [1]
Source
[1] https://www.drugpatentwatch.com/p/rinvoq-upadacitinib